Discovery of kisspeptin and its receptor has enhanced our understanding of the neurobiological mechanisms that govern the pituitary-gonadal-axis. However, in sexually immature male mammals, the maturation of gonads is not clear yet. The current study tested the hypothesis that continuous kisspeptin administration suppresses gonadotropin and testosterone release and spermatogenesis. Intraperitoneal kisspeptin administration was carried out in 05 weeks old prepubertal male Sprague Dawley rats, twice daily for 12 days, at three different dosage regimens: 10ρg, 1ηg and 1µg compared to control (saline-treated) rats. Effects on pituitary gonadotropins [Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH)], secretion of testosterone and spermatogenesis were evaluated on alternate day for one spermatogenic cycle. Major techniques applied were; radioimmunoassay, light microscopy and stereology. Histological study of spermatogenesis was done at stage VII of spermatogenic cycle. After the treatment, in all groups, no alterations were observed in the levels of plasma FSH. The concentrations of testosterone and LH were found to be significantly reduced in kisspeptin treated groups of 1µg dose (p<0.01) and 1ηg dose (p<0.05) whereas the dose of 10ρg had shown no significant change. Kisspeptin doses of 1ηg and 1µg lead to significant reduction in quantity of elongated spermatids and daily sperm production (p<0.05; p<0.001), step 7 spermatids (p<0.05; p<0.001), type A spermatogonia (p<0.05; p<0.01), pachytene spermatocytes (p<0.01; p<0.001) and preleptotene spermatocytes (p<0.05) whereas no significant decrease was observed with a dose of 10ρg. The present findings reveal that during non-pubertal stage; continuous administration of kisspeptin may suppress hypothalamic-pituitary-gonadal axis and spermatogenesis.